Caplyta is one of the few psychiatric drugs where shopping around barely helps. It is brand-only, there is no generic lumateperone on any American pharmacy shelf, and every strength costs the same. The number on the pharmacy receipt is roughly $1,762 for a month, and the only real levers are the manufacturer programs.

That makes this page short on price comparison and long on eligibility rules, because for a cash payer the eligibility rules are the price. Intra-Cellular Therapies, which developed the drug, is now part of Johnson & Johnson, so the live patient-support programs carry J&J branding and J&J terms. Every figure below was researched on September 4, 2026.

What Does Caplyta Cost Without Insurance?

Acquisition costs come from the CMS National Average Drug Acquisition Cost survey, effective August 19, 2026. That figure is what a pharmacy pays a wholesaler, not what a patient pays at the counter, and it is included here because it sets the floor that any cash price has to sit above. Cash retail comes from Drugs.com, read September 4, 2026. Medicare Part D figures are 2024 claims data, the most recent annual vintage CMS publishes.

OptionLowAverageHigh
CMS NADAC acquisition cost, one capsule$57.22906 (21 mg)$57.23629 (42 mg)$57.26523 (10.5 mg)
CMS NADAC acquisition cost, 30 capsules$1,716.87 (21 mg)$1,717.09 (42 mg)$1,717.96 (10.5 mg)
Cash price, 30 capsules, any strength$1,761.69$1,761.69$1,761.69
Cash price per capsule$58.72$58.72$58.72
Medicare Part D average spending per claim, 2024$1,686.17$1,686.17$1,686.17
Medicare Part D average spending per capsule, 2024$56.10$56.10$56.10
Twelve months of cash fills$21,140$21,140$21,140
CAPLYTA withMe Trial Offer, first 30-day supply$0$0$0
Johnson & Johnson Patient Assistance Program, if income-eligible$0$0$0

Three independent reads land within about 4% of each other, which is unusually tight. The pharmacy’s acquisition cost is roughly $1,717 for 30 capsules, Medicare’s average paid amount per claim was $1,686.17, and the cash counter price is $1,761.69. There is no meaningful spread to shop, because there is no second seller.

Volume gives a sense of what that adds up to. Medicare Part D alone covered 159,224 Caplyta claims for 27,010 people in 2024, at a total program cost of $268.5 million.

What Drives the Price

There is no generic, and that is the whole story. FDA’s Drugs@FDA records show Caplyta under new drug application 209500, approved December 20, 2019, held by Intra-Cellular. Five generic applications exist, from Aurobindo, MSN Laboratories, Hetero, Alkem and Dr. Reddy’s, and every one of them carries a status of tentative approval granted between March 26 and August 6, 2025. Tentative approval means FDA finished its scientific review and the product still cannot be sold, because patents or exclusivity block launch. Drugs.com’s availability page puts the earliest patent expiry at March 12, 2028, with method-of-use patents running to 2039 and 2040.

Strength does not matter. The 10.5 mg, 21 mg and 42 mg capsules cost a pharmacy within four hundredths of a cent of each other, and Drugs.com prices all three identically. This is the opposite of how generic markets behave, where price tracks the amount of active ingredient. Here you are buying a capsule, not milligrams.

Whether you have commercial insurance decides everything. A commercially insured patient can use the savings card and may pay as little as $0. A cash payer cannot use it at all. That single yes-or-no question is worth about $1,762 a month, which is larger than every other factor on this page combined.

Which J&J program you qualify for. After the acquisition, Caplyta support runs through CAPLYTA withMe. There are three distinct programs with three different eligibility rules, and they are easy to confuse: a savings card (commercial insurance only), a trial offer (open to everyone, one time), and the Johnson & Johnson Patient Assistance Program (income-tested, uninsured or underinsured).

The prescriber relationship, which is a recurring cost of its own. Caplyta requires ongoing prescribing, and if you are paying cash for the drug you are usually paying cash for the visits too. Our psychiatrist cost guide covers what those appointments run.

Cash Price vs. Insurance

This is the rare drug where paying cash is almost never the better play. At $1,761.69 a month, a cash fill is more expensive than nearly any specialty-tier copay, and money spent outside a plan does not count toward your deductible or out-of-pocket maximum. If you have commercial coverage, use it, then stack the savings card on top of it.

The trap on the insured side is prior authorization. Caplyta is a brand-only drug in a class stuffed with cheap generics, so plans routinely require you to have tried something else first. If a plan denies it, the savings card still helps: the program requirements say eligible patients whose insurance does not cover Caplyta, or whose coverage restrictions have not been met, pay as little as $0 on the first 30-day fill, once per lifetime.

If you are uninsured, the honest framing is that you should not be trying to buy this at retail at all. $21,140 a year is not a bill most households can absorb, and the manufacturer knows it, which is why the patient assistance program exists and is generous. Applying takes paperwork, not money.

If a pharmacy quotes you something far off the roughly $1,762 mark in either direction, run it through our fair price checker before you hand over a card. On a drug with a single national price, a wildly different quote is a data-entry problem, not a deal.

How to Pay Less

  1. Ask the prescriber for the trial offer first. The CAPLYTA withMe Trial Offer covers one 30-day supply at no cost and its published requirements say it is open to patients who have commercial insurance, government coverage, or no insurance coverage. That last clause is unusual and is the exception to the general rule that manufacturer cards exclude cash payers. It is one use per lifetime, must be a new prescription, and the terms expire at the end of each calendar year. Only a prescriber can hand it to you.

  2. Apply to the Johnson & Johnson Patient Assistance Program. This is the real answer for an uninsured reader. Caplyta appears by name on the program’s eligible-medicines list, and the guide sets the threshold at household income at or equal to 300% of the federal poverty level. The 2026 limits are $46,950 for a household of one, $63,450 for two, $79,950 for three and $96,450 for four in every state except Alaska and Hawaii, which are higher, plus $16,500 for each person beyond seven. Approved patients receive the medicine at no cost for up to one year. You will need a recent 1040, proof of a US address, and a signed prescriber section, and the program runs a credit check that does not affect your score. Eligibility does not depend on citizenship.

  3. Do not waste time on the savings card if you are uninsured. The June 2026 program requirements are explicit that the card is only for people using commercial or private insurance who must pay an out-of-pocket cost, and that patients on Medicare, Medicaid, TRICARE, VA or Department of Defense coverage are excluded. The terms also carve out plans that partner with SaveOnSP and reduce the annual maximum for patients in accumulator or maximizer programs, except in Maine. Reading the terms takes five minutes and saves a wasted trip.

  4. Ask the prescriber whether a generic molecule is appropriate for you. This is a clinical question, not a shopping decision, and the answer may well be no. But it is worth raising, because the price gap is enormous. Generic quetiapine runs $9 to $15 for 30 tablets and generic aripiprazole runs $7 to $18 for 30 tablets against $1,762 for Caplyta. If a cheaper molecule is not right for you, the other brand-only options in this class are not cheaper either: see our Vraylar, Rexulti and Latuda guides.

  5. Get the prescribing relationship somewhere affordable. A free or sliding-scale clinic can often handle the visits and the assistance paperwork at little or no cost, and community health centers are usually more practiced at manufacturer applications than a private office is. Our comparison of GoodRx vs. SingleCare is worth a read for the rest of your prescriptions, though be realistic: discount cards do very little on a brand-only drug at this price.

  6. If a bill has already landed, treat it as negotiable. Pharmacy bills are less flexible than hospital bills, but if the Caplyta charge arrived as part of an inpatient or facility bill, it is very much in play. Start with our guide to negotiating medical bills and check whether the facility owes you charity care before you pay anything.

Bottom Line

Budget about $1,762 for 30 capsules if you are paying cash in September 2026, at any of the three strengths, and understand that this number will not move until a generic launches. Five generic makers already hold tentative FDA approval, so the drug is queued up for a price collapse, but the earliest listed patent expiry is March 2028 and the method-of-use patents run far longer.

Until then, the money is in the paperwork. The trial offer covers one free month for anyone including the uninsured, the savings card covers commercially insured patients only, and the Johnson & Johnson patient assistance program covers income-qualified patients at up to 300% of the federal poverty level for a year at a time. If you are paying $1,762 a month out of pocket for Caplyta and have not applied to that program, that is the first phone call to make.